


GLYCOMARK® Test

Clinical Interpretation Guide - Detailed



*Normal GLYCOMARK results are lower in females than in males. Refer to gender specific ranges in the product package insert for more information.

Glycomark results represent glycemic control during the prior 1 to 2 weeks.

Repeat test in as soon as 2 weeks to reassess glycemic control, response to treatment or compliance.

Interpreting GLYCOMARK Results with A1C

	A1C < 7% (At Goal)	A1C ≥ 7% (Above Goal)
GLYCOMARK 10 - 31 µg/mL* NORMAL	<p>Concordant</p> <ul style="list-style-type: none"> Continued good control. No recent hyperglycemia or hyperglycemic excursions. 	<p>Discordant</p> <ul style="list-style-type: none"> Prior poor control, recent improvement. Fewer hyperglycemic excursions. Suggests compliance, response to therapy.
GLYCOMARK < 10 µg/mL* ABNORMAL	<p>Discordant</p> <ul style="list-style-type: none"> Prior good control, recent worsening. Hyperglycemic excursions likely occurring postprandially, perhaps with glycemic variability.² If due to glycemic variability, future A1C results may remain stable. Consider more frequent SMBG, closer evaluation of postprandial control, CGM, or treatment modifications. 	<p>Concordant</p> <ul style="list-style-type: none"> Continued poor control. Suggests low effectiveness of treatment or non-compliance. Consider more frequent SMBG, closer evaluation of postprandial control, CGM, or treatment modifications.

SMBG, self-monitoring blood glucose. CGM, continuous glucose monitoring.

GLYCEMIC TEST TARGETS³

Test	Goal
A1C	<7%
Postprandial Glucose	<180 mg/dL

**The lower the GLYCOMARK result,
the more severe the hyperglycemia**

¹GLYCOMARK Test Product Package Insert, Revision G, 2017. ²American Diabetes Association. *Medical Management of Type 2 Diabetes*, 7th edition, 2012. ³American Diabetes Association. *Diabetes Care* 2020; 43(Suppl. 1): S66-S76.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GLYCOMARK test in the treatment of the patient. Please refer to the GLYCOMARK product insert for more information.

The GLYCOMARK test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GLYCOMARK test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

GLYCOMARK, Inc. is the exclusive licensee of the GLYCOMARK test, trademark and logo. All other trademarks cited herein are the property of their respective owners.
© 2020 GLYCOMARK, Inc. All Rights Reserved. M-92-1A

GlycoMark[®]

805 Third Avenue, 17th Floor
New York, NY 10022
1-888-744-0221
info@glycomark.com
www.glycomark.com